Page 1

MetaViaM MetaVia Reports Second Quarter 2026 Financial Results and Provides Corporate Update All Active Patients Successfully Reached Highest Planned Dose Levels of 48 mg and 64 mg in Ongoing Phase 1 Part 3 Study of DA - 1726 16 - Week Topline Data Expected in the Fourth Quarter of 2026 - MetaVia Inc. ( CAMBRIDGE , Mass . , August 6 , 2026 Nasdaq MTVA ) , a clinical- stage biotechnology company focused on transforming cardiometabolic diseases , today announced financial results for the second quarter ended June 30 , 202 , and provided a corporate strategic update . e " During the second quarter of 202 , and subsequently , we continued to ecute across both of our clinical development programs while further strengthening the differentiated profile of DA - 172 as a dual GLP - 1 / glucagon receptor agonist , " stated Hyung Heon Kim , President and Chief E ecutive Officer of MetaVia . " Most recently , all active patients in both cohorts of our ongoing Phase 1 Part 3 study successfully , reached the highest planned dose levels of 48 mg and mg , representing an important e ecution milestone as we prepare for our 1 -week topline data readout , e pected in the fourth quarter of 202 Also of note , during the quarter , we presented additional data from our 48 mg Phase 1 study of DA - 172 at both the EASL and ADA scientific conferences , which demonstrated up to 9.1 % mean weight loss after just eight weeks of treatment , meaningful reductions in waist circumference and encouraging liver - related findings , reinforcing our confidence in DA - 172 ' s potential best - in - class profile and its potential to address multiple aspects of cardiometabolic disease . Based on the continued trajectory of weight loss through eight weeks without evidence of plateau on the 48 mg dosage , we believe the ongoing 1 -week study evaluating the 48 mg and higher mg dosages has the potential to provide a more complete assessment of the drug's effects on weight loss , waist circumference , cardiometabolic health and liver - related outcomes . " " In parallel , we continued to broaden the potential clinical utility of vanoglipel ( DA- 1241 ) . During the quarter , we presented preclinical combination data at the ADA 202 Scientific Sessions , demonstrating synergistic effects with both resmetirom in MASH and metformin in type 2 diabetes , while a peer - reviewed publication further highlighted the anti - fibrotic potential of GPR119 agonism . Together , these findings reinforce our strategy of advancing vanoglipel as a differentiated combination backbone for metabolic and liver diseases , designed to complement established and emerging therapies across cardiometabolic disorders . " Second Quarter 2026 and Subsequent Highlights • July 202 Announced the completion of dose titration in the 1 -week , Phase 1 Part 3 study of DA - 172 , with all active patients successfully reaching the highest planned dose levels of 48 mg and mg . June 202 Presented new late - breaking data at the ADA 202 Scientific Sessions supporting DA - 172 ' s differentiated obesity profile and demonstrating the combination potential of vanoglipel with resmetirom in MASH and metformin in type 2 diabetes . ני I